Articles by Tian Zhang, MD
View the live recording of the "The Uromigos' Definition of Oligometastatic" session from Uromigos Live 2024.
View the IO Rechallenge panel session from Uromigos Live & Unplugged 2024, recorded live in Nashville.
The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC.
The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades.
The panel explores our understanding of nccRCC, including classification, molecular distinctions, and prognostic criteria.
Dr. Zhang expands on treatment outcomes for patients with prostate cancer after imaging with Ga68-PSMA-PET.
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
The panel shared their approach to treatment selection for clear cell kidney cancer.
The panel provides their concluding thoughts on the frontline and refractory RCC treatment landscape.
The panel discusses treatment options in the refractory RCC setting.
The panel discusses what is most exciting to them in the frontline RCC field.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.